Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.62 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.62 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.59 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.58 |
| ▸ | EML4 | Q9HC35 | 2/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.57 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19440572 | 0.90 | EGFR (0.60) | EGFRFGFR4FGFR2FGFR3ALK | |
| SCHEMBL19753754 | 0.88 | EGFR (0.61) | EGFRALKEML4ERBB3 | |
| SCHEMBL17857097 | 0.87 | FGFR4 (0.56) | EGFRFGFR4FGFR2FGFR3FGFR1 | |
| SCHEMBL22819201 | 0.83 | EGFR (0.65) | EGFRALKEML4ERBB3 | |
| SCHEMBL17857076 | 0.83 | EGFR (0.44) | EGFRFGFR4FGFR2FGFR3ALK | |
| SCHEMBL17856998 | 0.83 | FGFR4 (0.68) | FGFR4FGFR2FGFR3FGFR1 | |
| SCHEMBL19089502 | 0.83 | EGFR (0.62) | EGFRALKEML4 | |
| SCHEMBL35210346 | 0.83 | EGFR (0.62) | EGFRALKEML4 | |
| SCHEMBL35210282 | 0.81 | EGFR (0.58) | EGFRALKEML4 | |
| SCHEMBL19089418 | 0.81 | EGFR (0.58) | EGFRALKEML4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906878-B2 | Kinase inhibitors for the treatment of disease | DANA FARBER CANCER INSTITUTE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190256475-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-08-22 | — | — | US | disclosed |
| US-10316002-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20170369449-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-28 | — | — | US | disclosed |
| US-9783504-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783504-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160176825-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| US-20160176825-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256475-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | BLK, ROS1, TEC | EGFR 24/4885FGFR4 40/4885FGFR2 22/4885 |
| US-20170369449-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | BLK, ROS1, TEC | EGFR 24/4885FGFR4 40/4885FGFR2 22/4885 |
| US-10906878-B2 | Kinase inhibitors for the treatment of disease | BLK, ROS1, TEC | EGFR 24/4885FGFR4 40/4885FGFR2 22/4885 |
| US-10316002-B2 | Kinase inhibitors for the treatment of disease | BLK, ROS1, TEC | EGFR 24/4885FGFR4 40/4885FGFR2 22/4885 |
| US-20160176825-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | BLK, ROS1, TEC | EGFR 24/4885FGFR4 40/4885FGFR2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.